The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in small
New payment models, dedicated investment, and better health technology assessment are among a raft of changes needed to bring regenerative medicines to patients in Europe, according to a ne
The trial of Sangamo’s gene-editing treatment for a rare and debilitating disease has got off to a good start, with no safety concerns reported so far.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.